Grace Therapeutics (GRCE)
Developing alternative-delivery therapies from established drugs.
Something off on this page? Send us feedback.
Develops alternative-delivery drug candidates from established active ingredients, led by injectable nimodipine program GTx-104; prospective economics depend on approval and commercialization or partnering, with no established commercial product base.
Develops GTx-104, an injectable nimodipine candidate for aneurysmal subarachnoid hemorrhage, alongside GTx-102, an oral mucosal betamethasone spray for ataxia-telangiectasia, and GTx-101, a topical bupivacaine spray for postherpetic neuralgia. GTx-104 addresses a neurocritical-care delivery problem when oral dosing can be difficult.
Uses established active ingredients with alternative delivery routes, pursuing U.S. 505(b)(2) submissions rather than discovering new molecules. GTx-104 carries most of the current operating weight after FDA review issues prompted a planned resubmission. The business has no established commercial product base and depends on approval, commercialization or partnership, external financing, and product-specific clinical, manufacturing, and review requirements.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Apr 24, 2026 | Craig-Hallum | Target | $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.8M · Total debt $0 · Total assets $50.1M · Shareholders' equity $48.2M
- Revenue
- $0
- Operating income
- −$15.8M
- Net income
- −$15.8M
No dividends on record.
| Institutions36 holders · as of Mar 31, 2026 | 26.20% | 4.26M shares | |
| Insiders1 holder · as of May 8, 2025 | 8.13% | 1.32M shares | |
| Strategic holders2 holders · as of Aug 19, 2026 | 27.51% | 4.48M shares | |
| Otherremainder | 38.16% | 6.21M shares |
16.27M company shares as of Sep 2, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (21.04M in the company's Sep 3, 2026 report, 16.27M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Opaleye Management Inc.Strategic10 percent owner | 16.96% | 2.76M | Form 4filed Aug 19, 2026 ↗ |
ADAR1 Capital Management, LLCStrategic | 10.55% | 1.72M | 13Gfiled May 15, 2026 ↗ |
Orin HirschmanInsider | 8.13% | 1.32M | 13Gfiled May 8, 2025 ↗ |
Cerity Partners LLCInstitution | 5.22% | 849,055 | 13Fas of Mar 31, 2026 |
Eversept Partners, LPInstitution | 4.65% | 756,600 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Opaleye Management Inc. | 10 percent owner | +11,608 | $2.09 |
- Amneal Pharmaceuticals
Oral generic nimodipine versus injectable GTx-104.
- Quince Therapeutics
Late-stage A-T therapy development versus GTx-102.
- Dr. Reddy's Laboratories (ADR)
Oral generic nimodipine versus injectable GTx-104.
- Scilex
Prescription topical PHN treatment versus GTx-101.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Grace Therapeutics | $2.14 | 0.00% | $34.8M | — | — | — | — |
| Amneal Pharmaceuticals | $18.01 | −0.33% | $5.77B | 37.0 | 18.1 | 1.8 | +9.9% |
| Quince Therapeutics | $31.61 | −2.89% | $9.0M | — | — | — | — |
| Dr. Reddy's Laboratories (ADR) | $12.17 | +0.04% | $10.14B | 28.9 | 32.2 | 2.9 | −16.2% |
| Scilex | $5.34 | −1.11% | $45.4M | — | 57.2 | 1.4 | −22.8% |
| Median | 33.0 | 32.2 | 1.8 | −16.2% |